Bendamustine
drugOn this page
Also known as BendamustinaSID50125886SID144206324SID174007431SID170465340US9096627CY190602
Summary
Bendamustine (CHEMBL487253) is an approved small molecule (ATC L01AA09); indicated across 34 conditions including neoplasm and b-cell chronic lymphocytic leukemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: L01AA09
- Indications: 34 conditions
- Clinical trials: 282
- Chemistry: 358.3 Da · C16H21Cl2N3O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL487253 |
| Name | Bendamustine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 65628 |
| ATC | L01AA09 |
| Molecular formula | C16H21Cl2N3O2 |
| Molecular weight | 358.3 |
| InChIKey | YTKUWDBFDASYHO-UHFFFAOYSA-N |
SMILES: CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
IUPAC name: 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
Also known as: Bendamustina, Bendamustine, SID50125886, SID144206324, SID174007431, bendamustine, SID170465340, US9096627, CY190602, BENDAMUSTINE
Parent form; salt/anhydrous children: CHEMBL1201734
Patent coverage: 7,666 distinct patent families (30,877 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 30,651 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Histone deacetylase 3, Protein deacetylase HDAC6, Histone deacetylase 2, Prostaglandin G/H synthase 1, Histone deacetylase 5, Histone deacetylase 8, Histone deacetylase 1, Histone deacetylase 4, Polyamine deacetylase HDAC10.
Bioactivity
ChEMBL activities: 13 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HDAC6 | 8.22 | IC50 | 6 | nM | CHEMBL_ACT_16292423 |
| HDAC2 | 8.05 | IC50 | 9 | nM | CHEMBL_ACT_16287832 |
| HDAC1 | 8 | IC50 | 10 | nM | CHEMBL_ACT_24723610 |
| HDAC2 | 8 | IC50 | 10 | nM | CHEMBL_ACT_24723618 |
| HDAC6 | 8 | IC50 | 10 | nM | CHEMBL_ACT_24723624 |
| HDAC3 | 8 | IC50 | 10 | nM | CHEMBL_ACT_24723643 |
| HDAC4 | 8 | IC50 | 10 | nM | CHEMBL_ACT_24723644 |
| HDAC5 | 8 | IC50 | 10 | nM | CHEMBL_ACT_24723645 |
| HDAC1 | 7.77 | IC50 | 17 | nM | CHEMBL_ACT_16349784 |
| HDAC3 | 7.6 | IC50 | 25 | nM | CHEMBL_ACT_16353674 |
| HDAC10 | 7.14 | IC50 | 72 | nM | CHEMBL_ACT_16338106 |
| HDAC8 | 6.97 | IC50 | 107 | nM | CHEMBL_ACT_16356957 |
| PTGS1 | 5.24 | AC50 | 5804 | nM | CHEMBL_ACT_25206624 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
34 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| B-cell chronic lymphocytic leukemia | 3 | MONDO:0004948 | EFO:0000095 |
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| Hodgkins lymphoma | 3 | MONDO:0004952 | EFO:0000183 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| neoplasm of mature B-cells | 3 | MONDO:0004949 | EFO:0000096 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| MALT lymphoma | 3 | MONDO:0007650 | EFO:0000191 |
| marginal zone lymphoma | 3 | MONDO:0017604 | EFO:1000630 |
| mantle cell lymphoma | 3 | MONDO:0018876 | EFO:1001469 |
| angioimmunoblastic T-cell lymphoma | 3 | MONDO:0004977 | EFO:0000255 |
| follicular lymphoma | 3 | MONDO:0018906 | MONDO:0018906 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| acute lymphoblastic leukemia | 2 | MONDO:0004967 | EFO:0000220 |
| hairy cell leukemia | 2 | MONDO:0018935 | EFO:1000956 |
| peripheral T-cell lymphoma, not otherwise specified | 2 | MONDO:0004964 | EFO:0000211 |
| Waldenstrom macroglobulinemia | 2 | MONDO:0100280 | EFO:0009441 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| ovarian cancer | 2 | MONDO:0008170 | MONDO:0008170 |
| hematopoietic and lymphoid system neoplasm | 2 | MONDO:0002334 | MONDO:0002334 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| hereditary amyloidosis | 2 | MONDO:0018634 | MONDO:0019438 |
| autoimmune hemolytic anemia | 2 | MONDO:0020108 | MONDO:0018922 |
| lymphoid neoplasm | 2 | MONDO:0005157 | EFO:0001642 |
| myelodysplastic syndrome | 1 | MONDO:0018881 | EFO:0000198 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| chronic myeloid leukemia | 1 | MONDO:0011996 | EFO:0000339 |
| plasma cell leukemia | 1 | MONDO:0018689 | EFO:0006475 |
| B-cell acute lymphoblastic leukemia | 1 | MONDO:0004947 | EFO:0000094 |
| prostate carcinoma | 1 | MONDO:0005159 | EFO:0001663 |
| B-cell non-Hodgkin lymphoma | 1 | MONDO:0015759 | EFO:1001938 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 282.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 114 |
| PHASE1 | 56 |
| PHASE3 | 55 |
| PHASE1/PHASE2 | 42 |
| Not specified | 7 |
| PHASE2/PHASE3 | 4 |
| PHASE4 | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06761911 | PHASE4 | NOT_YET_RECRUITING | BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma |
| NCT01056510 | PHASE4 | COMPLETED | A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) |
| NCT03817853 | PHASE4 | COMPLETED | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma |
| NCT02970318 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL |
| NCT02972840 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL |
| NCT03336333 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL |
| NCT04002297 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation |
| NCT04666038 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of LOXO-305 (Pirtobrutinib) Versus Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
| NCT05023980 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
| NCT05139017 | PHASE2/PHASE3 | RECRUITING | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) |
| NCT05371093 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma |
| NCT05624554 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) |
| NCT06006117 | PHASE3 | RECRUITING | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
| NCT06084936 | PHASE3 | RECRUITING | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator’s Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma |
| NCT06091254 | PHASE3 | RECRUITING | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT06191744 | PHASE3 | RECRUITING | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
| NCT06363994 | PHASE3 | RECRUITING | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
| NCT06465446 | PHASE3 | NOT_YET_RECRUITING | A Study of IMM01 Plus Tiselizumab Versus Physician’s Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma |
| NCT06496308 | PHASE3 | RECRUITING | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment |
| NCT06522737 | PHASE3 | RECRUITING | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype |
| NCT06846671 | PHASE3 | RECRUITING | A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors |
| NCT06911502 | PHASE3 | RECRUITING | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) |
| NCT06970743 | PHASE3 | RECRUITING | A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors |
| NCT07139873 | PHASE3 | RECRUITING | A Study of DZD8586 Versus Investigator’s Choice in r/r CLL/SLL (TAI-SHAN6) |
| NCT00769522 | PHASE3 | COMPLETED | FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia |
| NCT00877006 | PHASE3 | COMPLETED | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study |
| NCT00991211 | PHASE3 | COMPLETED | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab |
| NCT01059630 | PHASE3 | COMPLETED | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin’s Lymphoma (GADOLIN) |
| NCT01073163 | PHASE3 | COMPLETED | Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) |
| NCT01077518 | PHASE3 | TERMINATED | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy |
| NCT01232556 | PHASE3 | TERMINATED | A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy |
| NCT01332968 | PHASE3 | COMPLETED | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (GALLIUM) |
| NCT01423032 | PHASE2/PHASE3 | COMPLETED | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) |
| NCT01569295 | PHASE3 | COMPLETED | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) |
| NCT01570049 | PHASE3 | UNKNOWN | Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma |
| NCT01657955 | PHASE3 | UNKNOWN | Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia |
| NCT01678430 | PHASE3 | UNKNOWN | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment |
| NCT01724021 | PHASE3 | COMPLETED | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3a |
| NCT01732926 | PHASE3 | TERMINATED | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas |
| NCT01776840 | PHASE3 | COMPLETED | A Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: neoplasm, B-cell chronic lymphocytic leukemia, plasma cell myeloma, non-Hodgkin lymphoma, Hodgkins lymphoma, lymphoma, neoplasm of mature B-cells, diffuse large B-cell lymphoma, MALT lymphoma, marginal zone lymphoma, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, follicular lymphoma